Melbourn, UK, 11 April 2024 — SPT Labtech is pleased to announce the appointment of Rob Walton as Chief Executive Officer (CEO) as of May 1st, 2024, succeeding former CEO David Newble.
Rob joins SPT Labtech from GE Healthcare, where he served as President & CEO for EMEA. Prior to that, he led the Asia Pacific region, based in Singapore. He also brings expertise in product management and R&D from his roles as Global General Manager for the Ultrasound Primary & Affordable Care business based out of the UK, and the Respiratory Care business based out of the USA. His pre-GE experiences included engineering and operations leadership at Ford and Unilever, and strategy consulting at Bain & Company.
Rob commented “I am excited to join SPT Labtech to help drive the next phase of growth for the business. SPT Labtech has an exceptional portfolio of technologies, which are uniquely positioned to support the future of life sciences research. We have a top class team and it is an honour to lead such an accomplished group of people.”
Michael Bauer, Global Co-Head of Healthcare at EQT stated "We are thrilled to welcome Rob to SPT Labtech. His appointment stands as a clear testament to SPT Labtech's exceptional products and growth prospects as well as EQT's governance model. We are very much looking forward to the cooperation."
Kieran Murphy, Chairperson added “We are delighted to welcome Rob, he is a dynamic leader with a diverse background of experiences and an excellent track record. I look forward to working with him to accelerate our plans, and deliver long-term value for our customers and stakeholders.
I would also like to take this opportunity to thank David Newble for his leadership of SPT Labtech, which saw the organisation achieve solid progress during challenging trading conditions.”
